Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement.

Wehrli, Marc; Oppliger Leibundgut, Elisabeth; Gattiker, Heinrich H; Manz, Markus G; Müller, Antonia M S; Goede, Jeroen S (2017). Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement. The oncologist, 22(4), pp. 480-483. AlphaMed Press 10.1634/theoncologist.2016-0354

[img] Text
Wehrli M. et al. Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasie with 8p11 Translokation and CWP110-FGFR1 Rearrangement.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (193kB) | Request a copy

This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation. The Oncologist 2017;22:480-483.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Wehrli, Marc and Oppliger Leibundgut, Elisabeth

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1549-490X

Publisher:

AlphaMed Press

Language:

English

Submitter:

Nicole Corminboeuf

Date Deposited:

15 May 2018 17:41

Last Modified:

22 Oct 2019 18:35

Publisher DOI:

10.1634/theoncologist.2016-0354

PubMed ID:

28242791

Uncontrolled Keywords:

Acute myeloid leukemia CEP110‐FGFR1 fusion protein Dasatinib Eosinophilia Imatinib

BORIS DOI:

10.7892/boris.111457

URI:

https://boris.unibe.ch/id/eprint/111457

Actions (login required)

Edit item Edit item
Provide Feedback